Photo by Nwato
DMT is expected to account for 73.5% of the global market.
According to GlobalData, the Alzheimer's disease (AD) market across eight major global markets (8MM) is expected to reach US$19.3b by 2033, with a CAGR of 23.4%.
This expansion has been attributed to the introduction of costly disease-modifying therapies (DMTs), an aging population, and the introduction of new symptomatic treatments for AD-related agitation and psychosis.
DMTs are expected to account for 73.5% of the global market, with a large share dominated by drugs targeting amyloid beta. However, beyond access to treatment, there are still unmet needs.
The new DMTs are thought to have moderate effects, sparking continued demand for more effective treatments that not only slow the progression of the disease but aim to stop it entirely.
Additionally, there remains a need for drugs that can improve cognition later in the disease and provide more effective treatment of secondary symptoms such as agitation and psychosis.
8MM = United States, France, Germany, Italy, Spain, United Kingdom, Japan and China
Join the Asian Healthcare Magazine Community
Now that you're here…
….There are many ways you can work with us to promote your company and connect with your customers. Our team can help you plan and create print and digital advertising campaigns on this website and in the print magazine.
We can also organize real-life or digital events for you and source thought leadership speakers as well as industry leaders (who may be your potential partners) to attend your events. We also run a number of awards programs that give you the opportunity to be recognized for your achievements during the year, and you can join as a participant or sponsor.
Let us help you drive business development through good partnerships!
